Search PubMed⌕ Search

Biomedical subjects

N Hara

Publications and source records attributed to N Hara.

At least 469 records · Page 26Linked to original sources
PubMed1978

[Fundamental and clinical studies of PC-904 in pediatrics (author's transl)].

The following studies were carried out in pediatric patients. 1. Serum levels of PC-904 were examined in 3 patients by 1 hour intravenous infusion of 20 mg/kg, reaching the peak of 22.5 approximately 25.5 microgram/ml at the end of infusion. Half life was 37 approximately 48 minutes. 2. Investigated in only 1 patient, the urinary excretion rate was 12.9% (0 approximately 6 hours). 3. The effect of PC-904 on blood pressure was examined in 1 patient, and no effect was observed. 4. Clinical effects of PC-904 were examined in 9 patients; urinary tract infection (6 cases) and Salmonella enteritis (3 cases). The daily dose was 32.6 approximately 93.0 mg/kg. The overall clinical effectiveness was 66.7%. As to causative organisms E. coli, Klebsiella and Salmonella were isolated. The clinical effects by the organisms were 100%, 0%, and 66.7%, respectively. 5. Slight elevation of GOT and GPT and eosinophilia were observed in each one case but these abnormalities rapidly returned to pre-treatment levels when the administration was discontinued. No other side effects were noticed.

Adolescent↗
PubMed1977

[Study of S-6437 in pediatrics regarding clinical efficacy, blood levels and urinary excretion (author's transl)].

S-6437 was orally given to 29 patients of 3 months to 12 years and 6 months of age who had respiratory or urinary tract infections. The daily dose used was 25 to 60 mg/kg divided in two doses. The following is the results of this study: 1. With 25 approximately 60 mg/kg/day, satisfactory results were obtained for upper respiratory tract infections. In lower respiratory tract infections, however, the effectiveness seemed not to be so good as that in upper respiratory tract infections. 2. Side effects such as diarrhea, loose stool, abdominal pain and eruption were observed but they were temporary. Therefore, the administration of S-6437 was not discontinued due to such side effects. 3. S-6437 was acceptable to elder children but some of children of 2 approximately 4 years of age disliked this preparation because it was not smooth in their mouths. Therefore, the preparation of S-6437 should be further improved. 4. Since it has been recognized that blood levels of cephalexin following the administration of S-6437 last for a longer period of time than regular cephalexin, S-6437 is considered to be a useful preparation. 5. B.I.D. and T.I.D. regimens of S-6437 will give clinical satisfaction to children over 6 years and ones under 6 years, respectively.

Administration, Oral↗
PubMed1975

Studies on the establishment of multi-drug-resistant strain BIO-4R of Streptococcus faecalis in the intestinal tract of germ-free mice. Bacterial interaction and effect of antibiotics.

Germ-free ICR mice were mono- or dicontaminated with a multi-drug-resistant strain BIO-4R of Streptococcus faecalis (BIO-4R) and Escherichia coli 026 : K60 (E. coli) and administered aminobenzyl penicillin (ABPC). BIO-4R was established in the intestinal tract at a level of 10(8) viable cells per gram of stool on the fourth day following oral inoculation and the BIO-4R population was stably maintained thereafter. The drug resistance of BIO-4R remained unchanged in the intestinal tract of gnotobiotes throughout the experiment. Highly resistant cells of E. coli were isolated from the feces of some dicontaminated mice after ABPC administration. However, it seems that the high resistance of these E. coli is not due to the transfer of resistance of BIO-4R to E. coli. All animals given a large amount of BIO-4R (10(8) cells) per os survived throughout the study period of two weeks without symptoms.

Ampicillin↗